Developed by Dr. Trent Jones and named for the child who first experienced its remarkable effects, the Noah strain is making amazing strides for those who experience frequent seizures due to intractable epilepsy. The product of years of cross-breeding and careful study, the Noah strain is a high CBD oil cannabis strain containing less than 0.3% THC—a precise ratio that makes it accessible to epilepsy sufferers of all ages.

The Noah strain is also rich in beneficial terpenes, containing significant amounts of Beta-Caryophyllene (shown to have a therapeutic affect on inflammatory conditions and autoimmune disorders), Limonene (sought after for its ability to combat cancer cells in lab testing and kill pathogenic bacteria), and Myrcene (known for its affect as an analgesic and anti-inflammatory compound), among others.

Unlike other high CBD oil strains currently in development for epilepsy sufferers, the Noah strain is not classified as marijuana. Because of its low THC content, the Noah strain is classified as an industrial hemp strain and is therefore federally legal under the USDA Farm Bill, Section 7606.

The Noah strain is approved for cultivation in Missouri under the state’s Industrial Hemp Permit, with a focus toward combatting drug-resistant seizure disorders.